MDM2 SNP309 accelerates colorectal tumour formation in women

Journal of Medical Genetics

Volumn 43, Issue 12, 2006, Pages 950-952

  Bond, Garetri L ^a   Menin, Chiara ^c   Bertorelle, Roberta ^c   Alhopuro, Pia ^d   Aaltonen, Lauri A ^d   Levine, Arnold J ^a,b  

^a INSTITUTE FOR ADVANCED STUDY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d BIOMEDICUM HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PROTEIN MDM2;

ADULT; AGED; ALLELE; ARTICLE; CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL TUMOR; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION STRUCTURE; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 33846133702     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2006.043539     Document Type: Article

References (10)

1. Bond GL, Hirshfield KM, Kirchhoff T, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006;66:5104-10.
2. Lind H, Zienolddiny S, Ekstrom PO, et al. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 2006;118:1275-8.
3. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, et al. The MDM2 promoter polymorphism SNP309T->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 2005;42:694-8.
4. Lain S, Lane D. Improving cancer therapy by non-genotoxic activation of p53. Eur J Cancer 2003;39:1053-60.
5. Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002;19:607-14.
6. Jones JS, Chi X, Gu X, et al. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res 2004;10:5845-9.
7. Kruger S, Bier A, Engel C, et al. The p53 codon 72 variation is associated with the age of onset of hereditary non-polyposis colorectal cancer (HNPCC). J Med Genet 2005;42:769-73.
8. Menin C, Scaini MC, De Salvo GL, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006;98:285-8.
9. Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 2005;5:3-8.
10. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.